-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
Today (November 4), the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that Janssen, a subsidiary of Johnson & Johnson, has submitted a listing application for the new AIDS drug, Ripivirin injection, and Get accepted
Screenshot source: CDE official website
According to an early press release issued by Janssen, Rilpivirin is a small (25 mg) oral non-nucleoside reverse transcriptase inhibitor (NNRTI), which has the characteristics of definite efficacy, safety and well tolerability
It is worth mentioning that the researchers also explored the "cocktail therapy" composed of ripavirin and other HIV therapies, and many of them have received regulatory approval
Among them, Cabenuva is an injection preparation composed of ripavirin and cabotegravir
According to the CDE announcement, the injection formulation of Ripavirin was submitted by Janssen Company this time
Reference materials:
[1] Drug Evaluation Center of China National Medical Products Administration.